Search

Your search keyword '"Jose Luis Cabriada-Nuño"' showing total 9 results
Start Over Author "Jose Luis Cabriada-Nuño" Topic hepatology
9 results on '"Jose Luis Cabriada-Nuño"'

2. Tu1986 TNF-Alpha Activity in Plasma From Patients With Inflammatory Bowel Disease Under Adalimumab and Infliximab Treatment Evaluated in a Cell-Based Assay

Author

Ignacio Marín-Jiménez, M. Barreiro-de Acosta, María Chaparro, H de la Fuente, Pablo M. Linares, Marisa Iborra, David Bernardo, Iván Guerra, Pedro Majano, Valle García-Sánchez, Jose Luis Cabriada Nuño, Luis Bujanda, and Javier P. Gisbert

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Inflammatory bowel disease, Infliximab, Internal medicine, Adalimumab, medicine, Tumor necrosis factor alpha, business, medicine.drug, Cell based
Published
2016
Full Text
View/download PDF

3. Sa1973 Loss of Anti-TNF Drugs Into Feces and Its Impact on Anti- TNF Serum Levels and Clinical Response in Crohn's Disease (CD) Patients

Author

Iván Guerra, Pablo M. Linares, Carlos Taxonera, Luis Bujanda, Javier P. Gisbert, María Chaparro, Ignacio Marín-Jiménez, Jose Luis Cabriada Nuño, and Mercedes Ramas

Subjects
Crohn's disease, Hepatology, business.industry, Gastroenterology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Immunology, medicine, 030211 gastroenterology & hepatology, Tumor necrosis factor alpha, 030212 general & internal medicine, business, Feces
Published
2016
Full Text
View/download PDF

5. Tu1291 Infliximab Serum Levels Do Not Predict Remission After the Induction Phase in Crohn's Disease Patients

Author

Alicia Algaba, R. Ferreiro, Borja Hernández-Breijo, Carlos Taxonera, Luis Menchén, Luis Bujanda, Pablo M. Linares, Francisco Mesonero, Belén Beltrán, María Mora, María Dolores Martín Arranz, Iván Guerra, Javier P. Gisbert, Fernando Gomollón, Laura Sempere, Irene Moraleja, Valle García-Sánchez, Luis G. Guijarro, Eva Iglesias Flores, Isabel Vera, Ignacio Marín-Jiménez, María Chaparro, Ander Arbelaiz, Marisa Iborra, David Olivares, Cristina Suárez Ferrer, Jose Luis Cabriada Nuño, Mercedes Ramas, Silvia Gómez Senent, and Manuel Barreiro-de Acosta

Subjects
Crohn's disease, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, Induction Phase, medicine.disease, business, Infliximab, medicine.drug
Published
2015
Full Text
View/download PDF

6. 538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn's Disease Patients

Author

María Chaparro, Iván Guerra, Carlos Taxonera, Isabel Blazquez Gomez, Jesus M. Banales, Fernando Bermejo, Valle García-Sánchez, Isabel Vera, Luis Menchén, Belén Beltrán, Beatriz Benitez Garcia, Ignacio Marín-Jiménez, María Dolores Martín Arranz, Luis Bujanda, Patricia Aguilar-Melero, Rocío González Ferreiro, Joaquín Hinojosa, Laura Sempere, Marisa Iborra, Jose Luis Cabriada Nuño, Borja Hernández-Breijo, Mercedes Ramas, Iago Rodríguez-Lago, Javier P. Gisbert, Luis G. Guijarro, Juan L. Mendoza, Francisco Mesonero, Pablo M. Linares, Yolanda Ber Nieto, and Manuel Barreiro-de Acosta

Subjects
Crohn's disease, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Induction Phase, medicine.disease, Correlation, Internal medicine, medicine, Adalimumab, business, medicine.drug
Published
2015
Full Text
View/download PDF

7. Tu1292 Quantification of the Concentration of Antibodies Against Infliximab (IFX) in Human Serum Using a Pure Antibody As Calibrator

Author

María Dolores Martín Arranz, Patricia Sanmartín-Salinas, Isabel Vera, Joaquín Hinojosa, María Chaparro, Carlos Taxonera, Iván Guerra, Borja Hernández-Breijo, Ignacio Marín-Jiménez, Luis Bujanda, Fernando Gomollón, Luis G. Guijarro, Laura Sempere, Marisa Iborra, Jorge Monserrat, Javier P. Gisbert, Antonio López-Sanromán, Irene de los Dolores Román Curto, D. Cano-Martínez, Jose Luis Cabriada Nuño, Manuel Barreiro-de Acosta, and Valle García-Sánchez

Subjects
Hepatology, biology, business.industry, Immunology, Gastroenterology, biology.protein, Medicine, Antibody, business, Infliximab, medicine.drug
Published
2015
Full Text
View/download PDF

8. Tu1293 Soluble TNF Serum Levels During the Induction Phase in Crohn's Disease Patients With Anti-TNF Treatment

Author

Isabel Vera, María Dolores Martín Arranz, Javier P. Gisbert, Laura Sempere, Manuel Barreiro-de Acosta, María Chaparro, Luis Bujanda, Joaquín Hinojosa, Ignacio Marín-Jiménez, Alicia Algaba, David Olivares, Marisa Iborra, Lidia Tardío, Iván Guerra, Ainhoa Rodriguez Pescador, Rocío González Ferreiro, Francisco Mesonero, María Teresa Arroyo, Borja Hernández-Breijo, Luis G. Guijarro, Carlos Taxonera, Virginia Matallana Royo, Belén Beltrán, Silvia Gómez Senent, Maria J. Perugorria, Jose Luis Cabriada Nuño, Mercedes Ramas, J. Cantero, and Valle García-Sánchez

Subjects
Crohn's disease, Hepatology, business.industry, Immunology, Gastroenterology, Medicine, Tumor necrosis factor alpha, Induction Phase, business, medicine.disease
Published
2015
Full Text
View/download PDF

9. Su1175 Fourth-Line Rescue Therapy With Rifabutin in Patients With Three H. pylori Eradication Failures

Author

Javier P. Gisbert, Angeles Perez Aisa, Xavier Calvet, Santiago Marcos, Ines Modolell, JoseLuis Gisbert, Javier Molina-Infante, Luis Rodrigo, Eloisa Lamas, Angel Cosme, Manuel Castro-Fernandez, and Jose Luis Cabriada Nuño

Subjects
medicine.medical_specialty, Rifabutin, Hepatology, business.industry, Gastroenterology, Amoxicillin, Metronidazole, Regimen, Levofloxacin, Clarithromycin, Internal medicine, medicine, Vomiting, medicine.symptom, Adverse effect, business, medicine.drug
Abstract

BODY: BACKGROUND: In some cases, Helicobater pylori infection persists even after 3 eradication treatments. AIM: To evaluate the efficacy of an empirical forth-line rescue regimen with rifabutin in patients with 3 eradication failures, extending the experience of an ongoing multicenter study. METHODS: Design: Multicenter, prospective study. Patients: Patients in whom the following 3 eradication treatments had consecutively failed: 1st treatment: PPI + clarithromycin + amoxicillin; 2nd treatment: quadruple therapy (PPI + bismuth + tetracycline + metronidazole); 3rd treatment: PPI + amoxicillin + levofloxacin. Intervention: In patients failing these 3 regimens, a 4th regimen with rifabutin (150 mg b.i.d.), amoxicillin (1 g b.i.d.) and a PPI (standard dose b.i.d.) was prescribed for 10 days. Outcome: Eradication was confirmed using the 13C-urea breath test 4-8 weeks after therapy. Compliance and tolerance: Compliance was determined through questioning and recovery of emptymedication envelopes. Incidence of adverse effects was evaluated by means of a questionnaire. RESULTS: One-hundred and twenty-one patients (mean age 50 years, 41% males, 27% peptic ulcer/ 73% functional dyspepsia) were included. Compliance: 8 patients did not take correctly the medication (in 6 cases due to adverse effects). Per-protocol and intention-to-treat eradication rates were 54% (95%CI=44-64%) and 52% (43-61%). Adverse effects were reported in 40 S-334 AGA Abstracts (33%) patients, the most frequent being: nausea/vomiting (severe in 2 patients), asthenia/ anorexia, abdominal pain, diarrhea, fever, metallic taste, myalgia, hypertransaminasemia, leucopoenia (,1,500 neutrophils), thrombopoenia (,150,000 platelets), headache, and aphthous stomatitis. Myelotoxicity resolved spontaneously in all cases. CONCLUSION: Even after 3 previous H. pylori eradication failures, an empirical fourth-line rescue treatment with rifabutin may be effective in approximately 50% of the cases. Therefore, rifabutinbased rescue therapy constitutes a valid strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results